Cardiovascular Medicine Book

Congestive Heart Failure

Coronary Artery Disease

Electrocardiogram

Examination

Hyperlipidemia

Hypertension

Miscellaneous

Pericardial Disorders

Obstetrics Chapter related topics

http://www.fpnotebook.com/

MibefradilAka: T-Type Calcium Channel Blocker

Advertisement

  1. Indications
    1. Chronic stable Angina
    2. Hypertension
  2. Mechanism
    1. Blocks calcium influx at 2 types of calcium channels
      1. L-type (long-acting) channels
        1. Blocked by standard Calcium Channel Blockers
      2. T-type (transient) channels
        1. Blocked uniquely by Mibefradil
        2. Activated at lower voltages
        3. Present in:
          1. Vascular smooth muscle
          2. Myocardial conduction system
        4. Absent in
          1. Ventricular myocardium
    2. Effect of Mibefradil
      1. Produces coronary and peripheral vasodilatation
      2. Does not result in reflex tachycardia
  3. Efficacy
    1. Antihypertensive
      1. More effective then Diltiazem
      2. As effective as Amlodipine and Nifedipine
      3. Synergistic effect with ACE Inhibitors
    2. Anti-Anginal
      1. Delays onset of ischemia during Exercise
      2. Increases Exercise tolerance
  4. Contraindications
    1. Sick Sinus Syndrome
    2. AV Block without a Pacemaker
  5. Drug Interactions
    1. Fatal arrhythmia risk with
      1. Terfenadine
      2. Astemizole
      3. Cisapride
    2. Increases levels of
      1. Tricyclic Antidepressant
      2. Cyclosporine
  6. Adverse Effects
    1. Dizziness
    2. Fatigue
    3. Light headedness
    4. Peripheral edema LESS common than others in class
  7. Dosing
    1. 50 mg PO qd (up to 100 mg PO qd)
  8. References
    1. (1997) Med Lett Drugs Ther 39:103

Mibefradil (C0286185)

Definition (MSH)A benzimidazoyl-substituted tetraline that selectively binds and inhibits CALCIUM CHANNELS, T-TYPE.
ConceptsOrganic Chemical (T109) , Pharmacologic Substance (T121)
MSHD020748
EnglishMibefradil, MIBEFRADIL PREPARATION
Spanishmibefradil
Parent ConceptsBenzimidazoles (C0005050), Tetrahydronaphthalenes (C0039673), Calcium Channel Blockers (C0006684), benzimidazole (C0053183)
SourcesMSH, NDFRT, RXNORM, SCTSPA, SNOMEDCT, VANDF
Derived from the NIH UMLS (Unified Medical Language System)



Navigation Tree